As these are the patients who stand to benefit the most from reliable non-invasive risk stratification (e.g., for adjuvant clinical trial enrollment), and early detection of metastases, the identification of HTR2B as a marker that enhances detection of CHCs in combination with gp100 to identify high risk uveal melanoma is important and timely. Here, PMEL is linked to uveal melanoma.